Results 111 to 120 of about 45,696 (262)

In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase–producing Klebsiella pneumoniae

Antimicrobial Resistance and Infection Control, 2018
Background In recent years, the incidence of carbapenem-resistant Enterobacteriaceae (CRE) infections has increased rapidly. Since the CRE strain is usually resistant to most of antimicrobial agents, patients with this infection are often accompanied by ...
Wenxia Zhang, Yan Guo, Jiayin Li, Yiyuan Zhang, Yang Yang, Dong Dong, Demei Zhu, Ping He, Fupin Hu   +8 more
doaj   +1 more source

Bacteriophage Therapy: Current Strategies and Future Perspectives

MedComm, Volume 7, Issue 3, March 2026.
This manuscript systematically reviews the expanding scope of phage applications. It moves beyond traditional antibacterial use to explore their role in precision therapies against drug‐resistant infections, their synergy with antibiotics, and advanced biomaterial‐assisted delivery systems.
Zihe Zhou, Hanyu Fu, Mengzhe Li, Zhongyu Han, Zhenchao Wu, Huahao Fan, Ning Shen, Jiajia Zheng   +7 more
wiley   +1 more source

Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of Pseudomonas aeruginosa in China from 2010 to 2022

Emerging Microbes and Infections
Ceftazidime-avibactam (CZA) resistance is a huge threat in the clinic; however, the underlying mechanism responsible for high-level CZA resistance in Pseudomonas aeruginosa (PA) isolates remains unknown. In this study, a total of 5,763 P.
Xi Li, Longjie Zhou, Tailong Lei, Xiaofan Zhang, Jiayao Yao, Jintao He, Haiyang Liu, Heng Cai, J. Ji, Yiwei Zhu, Yuexing Tu, Yunsong Yu, Hualing Zhou   +12 more
semanticscholar   +1 more source

A Study on Ceftazidime/Avibactam and Aztreonam Synergy Among Aztreonam-resistant Metallo-β-lactamase Producing Enterobacterales in a Tertiary Care Hospital

Mediterranean Journal of Infection, Microbes and Antimicrobials
Introduction: Global detection of bacteria harboring metallo-β-lactamase (MBL) genes has increased at an alarming rate. However, there is no concurrent increase in available antibiotics for treatment, which has turned these infections into a public ...
Adelyn D’SOUZA, Rachana SHETTY, Asha Pai KB   +2 more
doaj   +1 more source

Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia

Journal of Infection and Public Health
Ceftazidime-avibactam (CZA) is the preferred treatment for infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). This study aimed to investigate the prognostic factors of 28-day mortality and 14-day clinical failure in patients treated with CZA for CZA-susceptible CRKP bacteremia.Patients with CZA-susceptible CRKP bacteremia who ...
Yi-Tsung Lin, Shih-Neng Lin, Chien Chuang, Szu-Yu Liu, Yu-Chien Ho, Chih-Han Juan, Hsiang-Ling Ho, Sheng-Hua Chou   +7 more
openaire   +3 more sources

Necrotising Soft Tissue Infections: A Single Center's Case Series

International Wound Journal, Volume 23, Issue 3, March 2026.
ABSTRACT Necrotising soft tissue infection (NSTI) is a progressive disease with a time‐dependent prognosis; if not promptly treated, it can lead to significant morbidity as well as mortality. Early and aggressive surgical treatment is mandatory for appropriate management. This study reports the diagnostic and therapeutic pathway, surgical treatment and
Francesca Toia, Andrea Pio Cascino, Mara Franza, Marco Romeo, Antonino Speciale, Adriana Cordova, Massimiliano Tripoli   +6 more
wiley   +1 more source

In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis

Emerging Microbes and Infections
Ceftazidime-avibactam (CZA) is employed for the treatment of infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP). Resistance to CZA is frequently linked to point mutations in the blaKPC.
S. Shen, Chengkang Tang, Weiwei Yang, Li Ding, Renru Han, Qingyu Shi, Yan Guo, D. Yin, F. Hu   +8 more
semanticscholar   +1 more source

Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration

, 2017
Ceftazidime-avibactam administered at 1.25 g every 8 h was used to treat multidrug-resistant Pseudomonas aeruginosa bacteremia in a critically ill patient on continuous venovenous hemofiltration (CVVH).
Eric Wenzler, Larry H. Danziger, Scott Benken, Susan C. Bleasdale, Kristen L. Bunnell, Keith A. Rodvold   +5 more
core   +1 more source

Efficacy of ceftazidime-avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying blaKPC-2 [PDF]

, 2017
Efficacies of ceftazidime-avibactam (4:1 w/w) and ceftazidime were tested against ceftazidime-susceptible (blaKPC-2-negative), and meropenem- and ceftazidime-resistant (blaKPC-2-positive), Klebsiella pneumoniae in a 52-h, multiple dose, abdominal abscess
Pop-Damkov, P., Petar Pop-Damkov, Taryn Sleger, Slee, A.M., Laud, P.J., Sleger, T., Kevin M. Krause, Krause, K.M., Nichols, W.W., Andrew M. Slee, Gangl, E., Peter J. Laud, Eric Gangl, Wright W. Nichols   +13 more
core   +1 more source

In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex

PLoS ONE
Background Infections caused by Stenotrophomonas maltophilia and related species are increasing worldwide. Unfortunately, treatment options are limited, whereas the antimicrobial resistance is increasing.
B. Méndez-Sotelo, Mónica Delgado-Beltrán, Melissa Hernández-Durán, C. Colín-Castro, José Esquivel-Bautista, Sandra Angélica Ortega-Oliva, Jossué Ortíz-Álvarez, Rodolfo García-Contreras, R. Franco-Cendejas, Luis Esau López Jacome   +9 more
semanticscholar   +1 more source